Auro Laboratories Ltd

Auro Laboratories Ltd is rated Sell by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 03 February 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

Auro Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed below reflect the stock's current position as of 23 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Auro Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Auro Laboratories Ltd has been downgraded from a Hold to a Sell rating by MarketsMOJO as of 29 Dec 2025, reflecting a deterioration in its technical outlook alongside persistent financial challenges. The company’s Mojo Score has declined to 41.0, signalling caution for investors amid flat quarterly results, weak debt servicing ability, and a sideways technical trend.

Auro Laboratories, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its market evaluation following recent changes in its technical outlook and financial performance. While the company’s long-term returns remain impressive compared to broader market indices, mixed signals from valuation metrics and financial trends have influenced the latest assessment of its investment profile.

Auro Labs., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting nuanced shifts across key financial and technical parameters. This adjustment comes amid a backdrop of mixed performance indicators, including valuation concerns and subdued financial trends, which continue to shape investor perspectives.

Auro Laboratories Ltd has witnessed extraordinary buying momentum today, registering a sharp surge that propelled the stock to hit its upper circuit limit. The absence of sellers and a queue filled exclusively with buy orders signal a potential multi-day circuit scenario, underscoring robust investor interest in this Pharmaceuticals & Biotechnology company.

Auro Laboratories has reported stable financial performance for the quarter ending September 2025, with net sales reaching Rs 11.61 crore and significant improvements in key metrics. Despite a decline in PAT for the nine-month period, the company has outperformed the Sensex over the past three years.

Auro Laboratories Ltd., a Mumbai-based generic Active Pharmaceutical Ingredients manufacturer specialising in anti-diabetic compounds, reported a return to profitability in Q2 FY26 with net profit of ₹0.72 crores, reversing the ₹0.11 crore loss recorded in the previous quarter. However, the modest absolute profit figure and concerning long-term trends continue to weigh on investor sentiment, with the stock trading at ₹228.00 and carrying a market capitalisation of just ₹142.10 crores.

Auro Laboratories Ltd is experiencing notable buying activity, with a significant intraday surge. The stock has shown strong weekly gains, contrasting with its recent performance over longer periods. Current investor interest may be linked to developments in the pharmaceutical sector, contributing to heightened trading volatility.

Auro Laboratories has reached a new 52-week low of Rs. 159, reflecting a 20.55% decline over the past year. Despite a brief intraday gain, the stock experienced high volatility and is trading below key moving averages. The company faces ongoing challenges, including declining sales and consecutive quarterly losses.